You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015.
The company has shared an objective to reach 30% share by 2024 through organic and non-organic means, which it suggests will yield $1 billion in revenue.
In its Q1, overall revenue was $168 million, with cannabis at $70.4 million , with the balance in medical, wholesale and international, declined by 7% compared to a year ago by our estimate as the overall market grew 47%.
Another short-fall in adult-use cannabis sales could not only weigh on the stock, but it could also lead to write-downs of inventory or its production capacity potentially.
Understand complex financials and get the facts with a subscription to Alan Brochstein’s 420 Investor, the longest running cannabis stock due diligence platform trusted by investors for over 8 years.
To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter.
Get ahead of the crowd! If you are a cannabis investor and find value in our Sunday newsletters, subscribe to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013.
Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames.